News

UK Biotech & Life Sciences News

Follow the latest UK life sciences company news, including biotech funding rounds, pharma partnerships, product launches, clinical updates, infrastructure projects and commercial announcements.

Latest updates
Showing 133–144 of 243 stories

Mursla Bio Publishes Peer-Reviewed Validation of Tissue-Specific Extracellular Vesicle Platform

Mursla Bio has published a peer-reviewed study in the Journal of Extracellular Vesicles validating its NEXPLOR technology for isolating hepatocyte-derived extracellular vesicles from human plasma, where they identified 57% more proteins than bulk vesicle preparations and 86 proteins associated with liver disease against four in the bulk samples. The platform underpins its FDA Breakthrough Device-designated EvoLiver test, and the company is developing further tissue panels.

Funding & Grants13 Oct 2026

Undecimal Bio Raises €16M Seed to Target siRNA Delivery Beyond the Liver

Undecimal Bio, a Cambridge spin-out from Eleven Therapeutics, has raised a €16 million ($18 million) Seed round co-led by 4BIO Capital and IQ Capital, with Verve Ventures, Harel Tech, Entrée Capital, Kerna Ventures and Saras Capital participating. The funding will expand its DELiveri platform for directing siRNA medicines to defined cell types, progress its renovascular programmes and grow the team at its laboratories at the Cancer Research UK Cambridge Institute.

REPROCELL Launches REPROSKIN Human Skin Model as Both a Research Product and Contract Testing Service

REPROCELL has launched REPROSKIN, a full-thickness human skin model built from primary keratinocytes and fibroblasts grown in its Alvetex scaffold and developed with Durham University. It is available through REPROCELL Europe both as live tissue for researchers to use in their own labs and as a fee-for-service testing offering run by REPROCELL scientists.

Amphista Therapeutics Doses First Patient in Phase 1 Trial of BRD9 Degrader AMX-883

Amphista Therapeutics has dosed the first patient in BRAMLIE, a Phase 1 trial of AMX-883, its oral BRD9 degrader and first clinical-stage asset, in acute myeloid leukaemia and high-risk myelodysplastic syndrome. The trial opened after FDA authorisation in June 2026 and is expected to enrol about 54 patients regardless of mutational status, with a combination study alongside standard-of-care therapies planned after the monotherapy phase.